Xiuning Le MD PhD

292 posts

Xiuning Le MD PhD banner
Xiuning Le MD PhD

Xiuning Le MD PhD

@LeXiuning

Associate Professor Thoracic Head and Neck Medical Oncology MD Anderson Cancer Center

Houston, TX Katılım Mart 2020
365 Takip Edilen2K Takipçiler
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Please (re)watch the powerful Special Speech delivered by Dr. Ross Camidge @DRCamidge at #TTLC26 @IASLC An internationally renowned thoracic oncologist, Dr. Camidge shared something profoundly personal: his own diagnosis and treatment journey with stage IV #EGFR-mutant #NSCLC. His reflections were thoughtful and deeply human. It is a reminder that before we are physicians or patients, we are human beings: vulnerable yet resilient. Please: ❤️ Act with urgency. ❤️ Treat with respect and gentleness. ❤️ Move forward with courage and hope. @ShirishGadgeel @lungoncdoc @KarenReckampMD @TejasPatilMD
IASLC@IASLC

At #TTLC26, @DRCamidge shared powerful insights shaped by both clinical expertise and personal experience living with #lungcancer. His presentation reminds us why continued innovation in #lungcancer research is essential to improving patient outcomes every day. bit.ly/46YrbUc

English
0
9
32
2.5K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
❤️ ❤️ So happy and proud to wrap up a successful #TTLC26 @IASLC 💐🎊 👉 This year, we set new records: 🥇 🔥 the highest attendance, 🥇 🔥 the greatest number of submitted abstracts, and 🥇 🔥 unprecedented sponsorship support. 👉 This year, we hosted two extraordinary keynote speakers: my mentor Dr. John Heymach @MDAndersonNews and his mentor Dr. Bruce E. Johnson. Seeing multiple generations of thoracic oncology leadership on one stage was a powerful reminder that progress in our field is built on mentorship, collaboration, and legacy. Let it continue. ❤️ ❤️ Special appreciation to my dear co-chairs @ShirishGadgeel @KarenReckampMD and Dr. Paul Bunn, and outstanding @IASLC staff, especially Kelly Heemsbergen, for being consistently knowledgeable, responsive, and supportive behind the scenes. 👉 See you all again at hashtag #TTLC27
Xiuning Le MD PhD tweet media
English
1
8
49
1.9K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Join us for the 26th Annual Targeted Therapies of Lung Cancer Meeting in Huntington Beach 🌴 🏖️ , with nation's leading experts in thoracic oncology. lnkd.in/grFDmjVA With my co-chairs, Drs @ShirishGadgeel @KarenReckampMD, Paul Bunn, we especially encourage junior faculty and oncology fellows to participate. The meeting offers a unique opportunity for academic mentorship, scientific exchange, and meaningful connections with industry partners. @MDAndersonNews @oncodaily
IASLC@IASLC

The countdown to #TTLC26 is on! 🧬 Join leading minds to explore what’s next in clinical research and targeted therapies. Don’t miss the conversations shaping the future: bit.ly/3KP8GtL

English
1
8
36
3K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
For #EGFR #PACC mutation #lungcancer, novel TKIs are in active investigation, the next key questions are: 👉1. Single vs. compound PACC mutations 👉2. co-mutation's impact to treatment 👉3. tumor immune microenvironment difference 👉4. strategies for overcoming resistance. Thank you ❤️@gotoPER #WinterLung26 @EdgardoSantosMD @MarkSocinski for providing this dynamics discussion platform
Edgardo Santos, MD, FACP, FASCO@EddieSantosMD

Outstanding presentation by Prof Xiuning Le from MDACC on EGFR PACC mutation; the importance of identifying and reporting them and the new clinical trials in this space. Here at the 23th WLC. @LeXiuning @MarkSocinski @OncologyInst @FLASCO_ORG @gotoPER #WLC26 @edgardo_ny

English
3
9
44
3.7K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
📖 New online from our group at @MDAndersonNews Mechanisms of Resistance to Trastuzumab-DXd in #LungCancer 🔬✨ Key findings: 👉 Payload resistance driven by #SLFN11 loss and copy-number gains in the efflux pump ABCC1/MRP1 👉 Secondary #HER2 extracellular domain mutations at the antibody binding site (e.g., D582, F595) 👉 Tumors with acquired payload resistance or domain IV mutations retain HER2 signaling and remain sensitive to TKIs, including #zongertinib and #sevabertinib 💡 🎊 🔥 This is the first comprehensive preclinical and clinical investigation of #ADC #MoR in lung cancer, with direct therapeutic implications. jto.org/article/S1556-…
Xiuning Le MD PhD tweet media
English
2
47
165
14.7K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Congratulations to 🌟🎊Dr. Ximeng Liu for been selected for support from the Lung Cancer Research Foundation (@lcrf_org ) for her project: “Deciphering response and resistance mechanisms to firmonertinib in #NSCLC patients with #EGFR #PACC mutations.” 🔬💡 Our journey has been remarkable: 👉 2021: Defined #EGFR #PACC mutations as a distinct structure–function subgroup in lung cancer. 👉 2023–2024: Partnered with ArriVent Biopharma on the first prospective trial dedicated to EGFR PACC patients — 68% response rate and 16.0 months PFS with #firmonertinib. 👉 2025: Launched the first global randomized phase III trial in EGFR PACC–mutant NSCLC (ALPACCA/FURMO-006; NCT07185997) 🌍🧪 👉 2026–2027: With @lcrf_org support, Dr. Liu will lead efforts to decipher resistance mechanisms and shape next-generation therapeutic strategies. 🚀 More exciting developments are on the horizon. lungcancerresearchfoundation.org/research/our-i…
Xiuning Le MD PhD tweet media
English
0
1
29
2.5K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Women in Thoracic Oncology! #MaTOSLung2025 @KarenReckampMD @LauraAlderMD @maraantonoff @maryjofidlerMD @drshieldsmd @DDoroshow @JuliaRotow @AnaVManana @MNagasaka @christine_lovly @RachelSanbornMD @NaglaAKarimMD @Latinamd
Xiuning Le MD PhD tweet media
Dr. Luis E. Raez@LuisRaezMD

Our Faculty #MaTOSLung2025 #OncologyEducation #LungCancerCare @EddieSantosMD @LuisRaezMD @KarenReckampMD @NaglaAKarimMD @LauraAlderMD @LudaBazhenovaMD @JeffBradleyMD @DCarboneMD @yyelamin @maryjofidlermd @drgandara @BalazsHalmosMD @WadeIams @iyengarpuneeth @karenkellymd @chulkimMD @lexiuning @JessicaJLinMD @StephenVLiu @Christine_Lovly @LindaMThoracic @MNagasaka @luisraezMD @Joshua_Reuss @BiagioRicciutMD @latinamd @delvysra @EddieSantosMD @drshieldsmd @lungoncdoc @FSkoulidis @AnaVManana @maraantonoff

English
0
5
40
4.6K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
#FDA granted accelerated approval for #sevabertinib for #HER2-mutant #NSCLC 🎂 🌺 🩷 📖 In previously treated patients without prior anti-HER2 targeted therapies (SOHO-01, cohort D) 👉 ORR 64% 👉 Duration of Response 9.2 months 👉 PFS 8.3 months 👉 most common side effect is diarrhea Deep gratitude to patients and families who contributed to advancing Science and Medicine, and we thank our colleagues and pharma partners for making this possible. ❤️❤️❤️ @MDAndersonNews @lungoncdoc @herbloong @EGFRResisters @Exon20Group
OncLive.com@OncLive

BREAKING❗: @US_FDA Grants Accelerated Approval to Sevabertinib in HER2-Mutated Nonsquamous NSCLC Learn more about this regulatory decision in the article below. 👇 🔗onclive.com/view/fda-grant… #lcsm #oncology #FDAapproved

English
1
12
50
5.2K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Honored to present at @sitcancer for HARMONi-A trial final OS. 😃Echo @HTawbi_MD that we are marking evolution of PD-1 blockade. @MDAndersonNews @lungoncdoc @oncodaily @OncoViews
Hussein Tawbi, MD, PhD@HTawbi_MD

Dr. ⁦@LeXiuning⁩ presenting ⁦@sitcancer⁩ FINAL OS results from ivonescimab + carbo/pem in TKI-refractory EGFR-NSCLC, HR 0.74, p=0.019. Benefit strongest in pts with brain mets HR 0.61, regimen approved in China. Impressive results marking evolution of PD-1 blockade

English
3
16
56
6.8K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
I also want to thank the incredible teams at @MDAndersonNews, @broadinstitute , and @Bayer, we push the boundaries of precision oncology for patients. We delivered high quality work 💪 💪 💪 yet remain fun 😃 and humble ♥️ @NEJM @myESMO #ESMO25
Xiuning Le MD PhD tweet media
Hidehito HORINOUCHI@HHorinouchi

🔥BREAKING‼️ @NEJM 🆙 ✅Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 🎯mPFS (PreTx w/o HER2, Pre HER2-ADC, Tx-naive): 8.3m, 5.5m, and not reached 🎙️ @LeXiuning #ESMO25 #LCMS @myESMO @OncoAlert @Larvol nejm.org/doi/full/10.10…

English
7
19
118
18.5K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Honored to share my 🚀 SECOND simultaneous publication at #ESMO25 🚀, published in 📖 @AnnalsOfOncology 🎉 Our global leptomeningeal disease (#LMD) from #NSCLC cohort study (2,052 patients) sets benchmark outcomes for this rare population and generates hypotheses for interventional studies. Grateful 🙏 ❤️ to my mentors, colleagues, friends, and mentees for their collaboration and inspiration throughout this journey 😜. We will continue to work and move together @KelseyPanMD @Alfdoc2 @HwakeleeMD @danieltanmd #LungCancer @myESMO @AnnalsOfOncology @MDAndersonNews
Xiuning Le MD PhD tweet media
Meimei Zheng@Nicmmzh126

Thrilled to share our global, multicenter study on leptomeningeal disease in NSCLC. None of this is possible without the dedication of participating centers and shared commitment for the vulnerable pts! @ThomasW35874311 @LeXiuning @KelseyPanMD @danieltanmd @HwakeleeMD @Alfdoc2

English
1
21
92
12.3K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
What is on your calendar? #LungCancer #Berline #ESMO25 📅 Friday, Oct 17 Proffered: Metastatic NSCLC 😀Xiuning Le 😉– SOHO-01: Sevabertinib in HER2+ NSCLC @MDAndersonNews @lungoncdoc 👉Sanjay Popat – Beamion-Lung-01: Zongertinib in HER2+ NSCLC 1L @DrSanjayPopat 👉Yasir Elamin – NORTHSTAR: Consolidation with osimertinib @YYElamin 👉Pasi Janne – FLAURA2: High-risk populations 👉Tony Mok – ALEX OS @TonyMok9 📅 Saturday, Oct 18 Proffered: Non-met NSCLC & SCLC 👉Muhammad Furqan – Durvalumab + Ceralasertib maintenance in ES-SCLC 👉Martin Reck – MDT-BRIDGE 📅 Sunday, Oct 19 Presidential Symposium II 👉Shun Lu – HARMONi-6: Ivonescimab + chemo in SQC NSCLC 1L 👉Li Zhang – OptiTROP-Lung04: sac-TMT vs carbo/peme in EGFR-mut TKI-refractory 📅 Monday, Oct 20 Proffered: CNS 👉Daniel Heudobler – Nivo-ipi-Bev + chemo in untreated NSQ-NSCLC 👉Yi-Long Wu – Global study on leptomeningeal disease from NSCLC @Exon20Group @EGFRResisters @oncodaily @OncoViews @Larvol @OncLive
English
2
14
42
5.1K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Are we ready for ultra-precision oncology? 🔬✨ 📖 New online: rdcu.be/eIwG2 Differential impact of #EGFR #exon20 insertion location (near- vs. far-loop) on TKI sensitivity 👉 EGFRex20ins can be separated into two distinct groups: near-loop (A767-P772) and far-loop (H773-R776) insertions. 👉 Molecular dynamics simulations reveal that near-loop insertions have multiple conformational states and lower transitional energy than far-loop insertions. 👉 This leads to differential responses and PFS in some TKIs but not all. 💡 This study highlights how ultra-precision oncology should guide small molecule 💊💊💊drug development. @MDAndersonNews @Exon20Group @EGFRResisters @NatureComms @lungoncdoc @oncodaily @OncoViews
Xiuning Le MD PhD tweet media
English
4
34
91
7.9K

Keşfet

@DRCamidge @IASLC @ShirishGadgeel @lungoncdoc @KarenReckampMD @TejasPatilMD @MDAndersonNews @YYElamin